{{Rsnum
|rsid=2296840
|Gene=PSMB4
|Chromosome=1
|position=151399571
|Orientation=plus
|GMAF=0.1938
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PSMB4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 98.2 | 1.8 | 0.0
| HCB | 30.7 | 49.6 | 19.7
| JPT | 24.1 | 50.9 | 25.0
| YRI | 73.5 | 24.5 | 2.0
| ASW | 69.6 | 26.8 | 3.6
| CHB | 30.7 | 49.6 | 19.7
| CHD | 41.3 | 46.8 | 11.9
| GIH | 81.0 | 19.0 | 0.0
| LWK | 71.6 | 22.9 | 5.5
| MEX | 57.9 | 38.6 | 3.5
| MKK | 73.7 | 21.8 | 4.5
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2296840
|Name_s=
|Gene_s=PSMB4
|Feature=
|Evidence=PubMed ID:18504423
|Annotation=Based on an study on 284 Mexican Americans, this variant in the 5' UTR of PSMB4 is significantly associated with major depressive disorder (MDD). The results implicate that the specific UTR variation increases the risks for a T-cell dysfunction in MDD in the studied population.
|Drugs=desipramine; fluoxetine
|Drug Classes=
|Diseases=Depression
|Curation Level=Curated
|PharmGKB Accession ID=PA161748326
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2296840
|overall_frequency_n=409
|overall_frequency_d=10748
|overall_frequency=0.0380536
|n_genomes=13
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}